DLL3 targeting bispecific antibody - NovaRock Biotherapeutics
Alternative Names: Anti-DLL3 antibody; Delta like 3 (Drosophila) protein targeting bispecific antibodyLatest Information Update: 05 Mar 2024
Price :
$50 *
At a glance
- Originator NovaRock Biotherapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Small cell lung cancer
Most Recent Events
- 19 Feb 2024 Early research in Small cell lung cancer in USA (Parenteral) prior to February 2024 (NovaRock Biotherapeutics pipeline, February 2024)